We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
IMMU 17.02-4.0%10:56 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: stockdoc779/11/2019 10:04:20 AM
11 Recommendations

Recommended By

and 6 more members

  Read Replies (1) of 54006
Was surprised by the stock price movement yesterday. Rose some in the morning but then kept going higher all day on exceptionally high volume. Seems hard to reconcile just with somewhat disappointing 1062 results for DS. The sector was strong yesterday but we were well beyond that. Did some large shorts decide to cover yesterday?
The news flow should be good for the next month. I am particularly focused on the bladder cancer data. They would not have gotten an oral poster session as a late breaker if the results did not warrant that. My understanding is that although the trial has not fully enrolled, there may be enough data here to support an application for BTD. If that is the case, the results could be very significant for the stock price. It would mean we have a strong chance at a second indication and we are not betting everything on TNBC and the outcome of the ASCENT trial.
The filing of the BLA in October will also be a big step forward.
I would like to hope that B gets the BLA right this time, and CMC is resolved. If so, we should see 30 dollars by the spring.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext